Guardant360® Liquid—Leading today. Redefining tomorrow.
The first and only liquid biopsy to deliver genomic and epigenomic insights in one for the most complete view of cancer.*
Overview
Key features for Guardant360 Liquid
with variants detected at as low as 0.001% MAF.2
analyzed per patient.
turnaround time for fast treatment decisions.†3
for >92% of patients.‡
Unlock maximum insights today, with limitless potential for tomorrow.
Guardant360 Liquid taps into 19,000+ epigenomic signals through ever-expanding test features, enabling more precise treatment choices and response prediction.
Biomarker Panel
Guardant360 Liquid is guideline-complete across all advanced solid tumors.§2,4-7
Covered guideline-recommended biomarkers for common cancer types:
ALK, BRAF, EGFR, ERBB2, FGFR1, FGFR2, FGFR3, FGFR4, KRAS, MET, NRG1, NTRK1, NTRK2, NTRK3, RET, ROS1
AKT1, BRCA1, BRCA2, ERBB2, ESR1, FGFR1, FGFR2, FGFR3, NTRK1, NTRK2, NTRK3, PALB2, PIK3CA, PTEN, RET, MSI, TMB
BRAF, ERBB2, KRAS, NRAS, NTRK1, NTRK2, NTRK3, POLD1, POLE, RET, MSI
ATM, ATR, BARD1, BRCA1, BRCA2, BRIP1, CDK12, CHEK1, CHEK2, FANCA, FANCL, MLH1, MRE11, NBN, PALB2, PTEN, RAD51B, RAD51C, RAD51D, RAD54L, RB1, TP53, MSI, TMB
See the full panel.
NEW Features
One revolutionary test. Ever-expanding features.
Explore the latest test features, automatically added to reports at no extra cost.
Confidence Patient is Biomarker Negative
Confirm the absence of FDA-approved genomic biomarkers in lung and colorectal cancers when ctDNA results are negative.
Molecular Breast Subtype
Identify changes in HR, HER2, and TNBC subtypes with liquid biopsy to complement tissue IHC.
Molecular Lung Subtype
Identify changes in adenocarcinoma, squamous cell, and small cell subtypes with liquid biopsy to complement tissue IHC.
Pharmacogenomics
Optimize treatment and reduce toxicity by identifying alterations in CYP2D6, DPYD, HLA-B, TPMT, and UGT1A1.
Molecular Tumor Type
Predict primary and secondary tumor of origin with high accuracy and refine diagnosis for CUP.
The ultimate power behind cancer testing.
See more now
with multi-dimensional insights.
Do more today
with additional treatment options.
Discover more tomorrow
with continuous innovations.
Guardant tests# are covered by all major insurers, including Aetna, Anthem, Cigna, United Healthcare, and others, ensuring access for 300 million+ lives.
Important note: Guardant360 Liquid was developed as a Laboratory Developed Test (LDT), and its performance characteristics determined, by the Guardant Health Clinical Laboratory in Redwood City, CA, USA, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing. This test has not been cleared or approved by the US FDA.
MAF, mutant allele fraction; MSI, microsatellite instability; TMB, tumor mutation burden; ctDNA, circulating tumor DNA; HR, hormone receptor; HER2, human epidermal growth factor receptor 2; TNBC, triple negative breast cancer; IHC, immunohistochemistry; CUP, cancer of unknown primary.
* The first and only commercially available liquid biopsy to deliver genomic and epigenomic insights from a single input.
† Median turnaround time from sample receipt to results.
‡ More than 92% of patients are assigned $0 by their insurance for a Guardant360 test.
§ For genomic biomarkers.
# Refers to Guardant360/Guardant360 CDx liquid biopsy.
For a full list of diagnoses, download the Controlled Language for Diagnosis page.
For a full list of medical articles and drugs’ Prescribing Information, download the Gene Pocket Guide Reference List.
References: 1. Guardant Health Data on File. Brand Tracker. 2024. 2. Guardant360® Assay Specifications. October 14, 2024. Guardant Health, Inc. Redwood City, CA. 3. Guardant Health data on file. September 27, 2024. Guardant Health, Inc. Redwood City, CA. 4. Riely GJ, Wood DE, Ettinger DS, et al. NCCN Guidelines® Insights: Non-Small Cell Lung Cancer, Version 5.2024, NCCN clinical practice guidelines in oncology. Accessed June 1, 2024. https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf 5. Gradishar WJ, Moran MS, Abraham J, et al. NCCN Guidelines® Insights: Breast Cancer, Version 2.2024, NCCN clinical practice guidelines in oncology. Accessed June 1, 2024. https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf 6. Benson AB, Venook AP, Adam M, et al. NCCN Guidelines® Insights: Colon Cancer, Version 3.2024, NCCN clinical practice guidelines in oncology. Accessed June 1, 2024. https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf 7. Schaeffer EM, Srinivas S, Adra N, et al. NCCN Guidelines® Insights: Prostate Cancer, Version 4.2024, NCCN clinical practice guidelines in oncology. Accessed June 1, 2024. https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf